Kyverna Therapeutics has revealed plans to present updated clinical data from lupus nephritis (LN) patients treated with KYV-101 at the American College of Rheumatology (ACR) Covergence 2024.

The data are from the ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments.

The presentation will highlight all six patients treated with the target dose of 1×108 CD19 CAR-T cells, four of which have at least six months of follow-up.

All patients at six months of follow-up after treatment at the target dose continue to display sustained efficacy and durability across numerous key clinical measures.

“As our KYV-101 clinical datasets mature, we are increasingly able to focus on the right patients, treated at the right dose, with the right protocol. We are excited to share these new data, which continue to reinforce KYV-101’s potential for durable and life-changing outcomes in lupus nephritis patients, including those with high chronicity and disease severity,” said Warner Biddle, Chief Executive Officer at Kyverna.

The updates will be presented at a company symposium titled, ‘KYV-101 Anti-CD19 CAR T-Cell Therapy: The Future of Autoimmune Disease Treatment,’ to be held on 18 November 2024.

“Lupus nephritis patients encounter a tremendous burden of disease associated with high morbidity and mortality, with up to 30% of patients ultimately experiencing end-stage renal disease that requires dialysis or kidney transplant,” said Professor Georg Schett, from the Friedrich-Alexander-University in Erlangen, Germany, and one of the presenters.

“The data reinforce that treatment with KYV-101 drives deep B cell depletion in patients with LN, and appears to reset the immune system, stabilise eGFR, preserve kidney function and enable clinical improvement in SLE activity. Notably, this clinical benefit is occurring while also eliminating immunosuppressants and reducing glucocorticoids to physiologic levels with a manageable safety profile.”

Diana Spencer, Senior Digital Content Editor, DDW